318 related articles for article (PubMed ID: 35347591)
61. An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
Chung C; Lee R
J Oncol Pharm Pract; 2017 Sep; 23(6):454-469. PubMed ID: 27357817
[TBL] [Abstract][Full Text] [Related]
62. Major clinical research advances in gynecologic cancer in 2019.
Kim M; Suh DH; Lee KH; Eom KY; Lee JY; Lee YY; Hansen HF; Mirza MR; Kim JW
J Gynecol Oncol; 2020 May; 31(3):e48. PubMed ID: 32319232
[TBL] [Abstract][Full Text] [Related]
63. Major clinical research advances in gynecologic cancer in 2020.
Lee YY; Choi MC; Park JY; Suh DH; Kim JW
J Gynecol Oncol; 2021 Jul; 32(4):e53. PubMed ID: 34085794
[TBL] [Abstract][Full Text] [Related]
64. Advancing Drug Development in Gynecologic Malignancies.
Beaver JA; Coleman RL; Arend RC; Armstrong DK; Bala S; Mills GB; Sood AK; Herzog TJ
Clin Cancer Res; 2019 Aug; 25(16):4874-4880. PubMed ID: 31126961
[TBL] [Abstract][Full Text] [Related]
65. Chemotherapy for gynecologic malignancies.
Vermorken JB; Hoekman K
Curr Opin Oncol; 1995 Sep; 7(5):457-65. PubMed ID: 8541392
[TBL] [Abstract][Full Text] [Related]
66. Fertility-sparing options for patients with gynecologic malignancies.
Leitao MM; Chi DS
Oncologist; 2005 Sep; 10(8):613-22. PubMed ID: 16177285
[TBL] [Abstract][Full Text] [Related]
67. DNA damage response as a therapeutic target in gynecological cancers.
Leary A; Auguste A; Mesnage S
Curr Opin Oncol; 2016 Sep; 28(5):404-11. PubMed ID: 27455135
[TBL] [Abstract][Full Text] [Related]
68. Rational study endpoints in anti-neoplastic agent regulatory approval trials in the gynecologic malignancies.
Markman M
Womens Health (Lond); 2016 Jul; 12(4):396-9. PubMed ID: 27638892
[TBL] [Abstract][Full Text] [Related]
69. Genomic insights in gynecologic cancer.
Roddy E; Chapman J
Curr Probl Cancer; 2017; 41(1):8-36. PubMed ID: 28088330
[TBL] [Abstract][Full Text] [Related]
70. Biologic therapies and personalized medicine in gynecologic malignancies.
Schiavone MB; Bashir S; Herzog TJ
Obstet Gynecol Clin North Am; 2012 Jun; 39(2):131-44. PubMed ID: 22640707
[TBL] [Abstract][Full Text] [Related]
71. [Molecular targeting therapy for gynecologic cancer].
Nakayama K; Miyazaki K
Nihon Rinsho; 2012 Nov; 70 Suppl 8():524-8. PubMed ID: 23513895
[No Abstract] [Full Text] [Related]
72. Racial and ethnic enrollment disparities in clinical trials of poly(ADP-ribose) polymerase inhibitors for gynecologic cancers.
Wagar MK; Mojdehbakhsh RP; Godecker A; Rice LW; Barroilhet L
Gynecol Oncol; 2022 Apr; 165(1):49-52. PubMed ID: 35144798
[TBL] [Abstract][Full Text] [Related]
73. Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer.
Markman M
Womens Health (Lond); 2018; 14():1745505717750694. PubMed ID: 29313444
[TBL] [Abstract][Full Text] [Related]
74. Defective DNA repair in hereditary ovarian cancers: Implications for therapy.
Burgess BT; Kolesar JM
Am J Health Syst Pharm; 2018 Nov; 75(21):1697-1707. PubMed ID: 30228165
[TBL] [Abstract][Full Text] [Related]
75. Gynecologic Cancers: Emerging Novel Strategies for Targeting DNA Repair Deficiency.
Kristeleit RS; Miller RE; Kohn EC
Am Soc Clin Oncol Educ Book; 2016; 35():e259-68. PubMed ID: 27249731
[TBL] [Abstract][Full Text] [Related]
76. Targeted therapy in gynecologic cancers: Ready for prime time?
Seoud M; Lundqvist EÅ; Fujiwara K
Int J Gynaecol Obstet; 2015 Oct; 131 Suppl 2():S150-2. PubMed ID: 26433672
[No Abstract] [Full Text] [Related]
77. [Trends in comprehensive treatment for gynecologic malignancies].
Yakushiji M; Fujiyoshi K; Komai K; Imamura K
Gan To Kagaku Ryoho; 1999 Jun; 26 Suppl 1():145-56. PubMed ID: 10410669
[TBL] [Abstract][Full Text] [Related]
78. Highlights from the Society of Gynecologic Oncology's 50th Annual Meeting on Women's Cancer.
English DP; Huang M
Gynecol Oncol; 2019 Jun; 153(3):467-470. PubMed ID: 31023555
[No Abstract] [Full Text] [Related]
79. PI3K pathway in gynecologic malignancies.
Salvesen HB; Werner HM; Krakstad C
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714506
[TBL] [Abstract][Full Text] [Related]
80. New windows of surgical opportunity for gynecological cancers in the era of targeted therapies.
Peters I; Marchetti C; Scambia G; Fagotti A
Int J Gynecol Cancer; 2024 Mar; 34(3):352-362. PubMed ID: 38438181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
